iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,883 shares of iTeos Therapeutics stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $10.10, for a total value of $443,218.30. Following the sale, the chief executive officer now directly owns 135,903 shares of the company's stock, valued at $1,372,620.30. This trade represents a 24.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Michel Detheux also recently made the following trade(s):
- On Friday, June 6th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $448,035.22.
- On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $85,764.00.
- On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $84,840.00.
iTeos Therapeutics Stock Down 1.3%
ITOS stock traded down $0.13 during trading on Monday, hitting $10.04. The company had a trading volume of 1,104,582 shares, compared to its average volume of 661,405. The firm has a market cap of $384.27 million, a PE ratio of -3.19 and a beta of 1.51. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.13. The firm has a 50-day moving average price of $7.38 and a 200-day moving average price of $7.47.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14. Sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.
Hedge Funds Weigh In On iTeos Therapeutics
Several institutional investors have recently added to or reduced their stakes in ITOS. BVF Inc. IL acquired a new position in iTeos Therapeutics in the 4th quarter valued at about $17,856,000. JPMorgan Chase & Co. increased its position in iTeos Therapeutics by 342.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after acquiring an additional 1,601,477 shares during the period. RA Capital Management L.P. increased its position in iTeos Therapeutics by 74.4% during the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock worth $21,785,000 after purchasing an additional 1,556,798 shares during the period. Boxer Capital Management LLC acquired a new position in iTeos Therapeutics during the 4th quarter worth approximately $7,272,000. Finally, 683 Capital Management LLC increased its position in iTeos Therapeutics by 90.6% during the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock worth $10,448,000 after purchasing an additional 831,883 shares during the period. Institutional investors and hedge funds own 97.16% of the company's stock.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Raymond James set a $12.00 target price on iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Wells Fargo & Company reissued an "equal weight" rating and issued a $12.00 target price (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Finally, Piper Sandler reissued an "overweight" rating and issued a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $15.86.
Check Out Our Latest Stock Report on iTeos Therapeutics
iTeos Therapeutics Company Profile
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Recommended Stories
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
